Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Fallopian Tube Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

8 recruiting trials for Fallopian Tube Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 8 Fallopian Tube Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 40% (2 studies); the largest phase groups are Phase 2: 2, Phase 1 / Phase 2: 2, Early Phase 1: 1.

Research is led by Shanghai Gynecologic Oncology Group (2), Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1), H. Lee Moffitt Cancer Center and Research Institute (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Bevacizumab (drug, 2 trials), followed by Standard of care, Aspirin 325mg.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
0
Phase 3 Trials
7
Sponsors

Track Fallopian Tube Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05574673

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of...

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials UnitEnrolling: 10001 location
RECRUITINGEarly Phase 1NCT05080946

Using Aspirin to Improve Immunological Features of Ovarian Tumors

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1004 locations
RECRUITINGNCT05912972

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer...

Sponsor: Asan Medical CenterEnrolling: 135001 location
RECRUITINGPhase 2NCT06014190

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a...

Sponsor: Hansoh BioMedical R&D CompanyEnrolling: 46020 locations
RECRUITINGPhase 2NCT05200260

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Sponsor: Shanghai Gynecologic Oncology GroupEnrolling: 2209 locations
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid...

Sponsor: GenmabEnrolling: 88420 locations
RECRUITINGNCT05236686

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian...

Sponsor: Shanghai Gynecologic Oncology GroupEnrolling: 941 location

Frequently Asked Questions

There are currently 8 clinical trials for Fallopian Tube Cancer, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Fallopian Tube Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Fallopian Tube Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.